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ABSTRACT
Coronary heart disease (CHD) is the major cause of death internationally, and yet most can be prevented 
using population-wide strategies by addressing behavioral risk factors, including reduction of blood 
cholesterol levels. Following the definition of clinical decision limits for cholesterol according to risk of 
CHD, an international effort was undertaken to establish traceability of routine clinical cholesterol assays 
to improve reproducibility and accuracy. This task has been achieved through the establishment of the 
Cholesterol Reference Measurement Laboratory Network. This work is associated with a reduction in the 
number of persons with elevated cholesterol levels and reduction in the death rates from CHD. It has 
been a major achievement for the discipline of laboratory medicine and a guide for future efforts for the 
improvement of patient outcomes.
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Introduction: Why is traceability of 
clinical laboratory lipid measurements 
important for the community?
Coronary heart disease (CHD) remains the leading 
cause of death worldwide with an estimated 17.5 million 
deaths in 2012, representing 31% of all global deaths [1]. 
Current opinion is that most cardiovascular diseases 
can be prevented using population-wide strategies by 
addressing behavioral risk factors such as tobacco 
use, unhealthy diet and obesity, physical inactivity and 
harmful use of alcohol. Recognised risk factors include 
hypertension, diabetes, hyperlipidaemia or already 
established disease, and such people need early detec-
tion and management with counselling and medicines, 
as appropriate [1]. Therefore, CHD is a major healthcare 
burden, for which there are at least three modifiable 
factors including high blood cholesterol levels. 
Conclusive evidence from randomized, controlled 
clinical trials demonstrating that lowering blood choles-
terol reduced the risk of CHD was published in 1984 [2], 
following which the National Cholesterol Education 
Program (NCEP) was established to reduce the preva-
lence of increased blood cholesterol [3]. By 1988, the 
NCEP had identified the following clinical limits for blood 
cholesterol: less than 5.2 mmol/L (200 mg/dL) was 
Desirable; 5.2 to 6.2 mmol/L (200 to 239 mg/dL) was 
Borderline and greater than 6.2 mmol/L (240 mg/dL) 
was High [4]. NCEP also undertook a high profile pub-
licity campaign under the slogan “Know your number 
and do something about it” to raise public awareness 
of the importance of knowing their blood cholesterol 
level [3]. This campaign generated unprecedented 
attention on the performance of clinical laboratories 
and the reliability of clinical cholesterol testing [5]. 
Therefore, the reliable measurement of blood choles-
terol became, initially a US, and later an international 
public health priority.
History of standardization of lipid 
testing
Already in 1957, a requirement for high quality blood 
cholesterol assays was being raised within the US, e.g. 
at the Conference on Longitudinal Cardiovascular Stud-
ies following the experience gained from researchers ex-
changing serum specimens amongst themselves [6, 7]. 
They were concerned by the wide range of results, and 
there was a general agreement that clinical cholesterol 
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assays needed to improve reproducibility and compara-
bility. The first Cooperative Cholesterol Standardization 
Program was established aiming to develop suitable 
serum-based reference materials for cholesterol with the 
initial specific tasks to determine if lyophilized human 
serum was a suitable medium, prepare highly purified 
cholesterol suitable for the use as a primary standard 
and to quantify variability of cholesterol testing at that 
time [8]. After extensive evaluation of reproducibility, 
the Abell-Kendall method for blood cholesterol mea-
surement was selected as the reference method, which 
remains today as conducted by or under the supervision 
of the laboratory of the US Centers for Disease Control 
and Disease Prevention (CDC). At this time, they found 
that this method was capable of a coefficient of variation 
of 1.5% [9].
Further work was encouraged when the National 
Heart Institute initiated collaboration with CDC in 
1961 following their recognition that many of the failed 
heart disease studies were attributable to questionable 
cholesterol measurements [8], demonstrating once 
again the well-known management adage “If you can’t 
measure it (or in this case measure it adequately), 
you can’t manage it”. In 1962, the World Health Or-
ganization (WHO) appointed CDC as a Collaborating 
Center for Reference and Research in Blood Lipids [8]. 
CDC’s role was to offer standardization assistance to 
international research laboratories supporting WHO 
studies of CHD. By 1965, services were being provided 
to 65 participating laboratories in the USA and 18 labo-
ratories internationally.
A major milestone in clinical chemistry was the de-
velopment of the first reference measurement system 
for cholesterol by the American Association of Clinical 
Chemistry (AACC) Cholesterol Reference Method Study 
group formed in 1975. The Abell-Kendall method was 
selected as the reference method, and isotope dilu-
tion-mass spectrometry (IDMC) was selected as the 
definitive method with the establishment of a further 
collaboration, this time with the National Institute of 
Science and Technology (NIST), the USA National 
Metrology Institute. Thus, the CDC Abell-Kendall ref-
erence method, the NIST IDMC definitive method, the 
NIST Standard Reference Material (SRM) 911 pure 
cholesterol primary standard and the serum reference 
materials prepared by CDC and offered by NIST made 
up the components of the National Reference System 
for Cholesterol [10]. This development represented the 
highest level of the application of metrological principles 
to laboratory medicine at that time, eventually initiating 
a major activity in standardization of clinical assays that 
continues today.
Clinicians and laboratory specialists now started 
collaborating to decide on the clinical requirements for 
blood cholesterol assays with regard to reproducibility 
and accuracy. The US National Heart, Lung, and Blood 
Institute launched the National Cholesterol Education 
Program (NCEP) aiming to diminish the prevalence 
of hypercholesterolemia to reduce CHD disease and 
death. NCEP adopted performance goals for clinical 
laboratory cholesterol testing such that the coefficient 
of variation (CV) was less than 3% and bias was not to 
exceed + 3% [11]. For clinical laboratories to achieve 
these recommendations, cholesterol testing in each 
laboratory had to be traceable to the NIST reference 
material SRM911. 
Application of traceability  
of cholesterol assays to routine  
clinical laboratories 
Following the public health campaign of the NCEP, 
the numbers of cholesterol test requests to clinical 
laboratories were increasing markedly. To cope with 
the large number of patient specimens it is impractical 
for clinical laboratories to perform reference methods 
on patient specimens. Therefore, a translation of the 
accuracy of the reference procedures to routine clinical 
procedures is required. This translation is known as 
establishing traceability of the routine procedures to the 
purified NIST SRM911. The problem for clinical assays is 
that patient cholesterol is in a complex matrix of serum 
which has the potential to interfere with routine clinical 
cholesterol assays. 
The initial work utilised lyophilized serum speci-
mens for which cholesterol had been measured by the 
reference method and, therefore, calibrated against 
SRM911. This was a satisfactory strategy while routine 
assays employed chemical methods. However, as the 
clinical requirement for patient analyses increased, the 
In Vitro Diagnostic industry expanded technology with 
the application of enzymes for the assay of blood cho-
lesterol. It was now found that the calibration of these 
assays was not accurate when lyophilised calibrators, 
controls or reference materials were used. Thus, these 
lyophilized materials were not commutable for the en-
zymatic cholesterol assays [12]. 
Commutability of assays is an essential 
requirement for traceability
Non-commutability of an assay is evident when ma-
trix-induced biases (matrix effects) change the analyte’s 
reactive properties between processed samples, such 
as the one which  occurs with lyophilization of serum, 
and patient specimens. Primary reference materials 
are usually purified chemicals, and primary, as well as 
secondary reference methods are usually independent 
of matrix effects because they involve extraction proce-
dures. However, when secondary reference materials 
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are prepared for the assessment of blood, plasma or 
serum-based assays, they have to be verified as com-
mutable with patient specimens. Such testing involves 
measuring the secondary reference materials and fresh 
patient specimens by a comparative method such as 
the Abell-Kendall reference method for cholesterol, and 
an evaluated method such as an enzymatic method for 
cholesterol. If the measured cholesterol levels in the 
patient pools do not describe the same relationship 
between the two methods as the fresh patient serum 
specimens, then secondary reference materials are 
not commutable.
A popular strategy to address this issue of 
non-commutability is to use fresh patient specimens. If 
relative large pools of suitable blood products are 
available, then this strategy is feasible. The CDC has 
developed considerable expertise in the preparation 
of such pools, which can be calibrated by a reference 
method, and aliquots of the calibrated serum pool can 
be stored and distributed to appropriate laboratories 
for calibration of working or routine methods. This 
strategy overcomes any commutability problems al-
though each pool has to be proven to be commutable 
with fresh patient specimens before being accepted 
and proven suitable for distribution as a secondary 
reference material [12].
The clinical assessment of lipids includes mea-
surements of blood High Density Lipoprotein (HDL) 
cholesterol and triglyceride with Low Density Lipo-
protein cholesterol usually being calculated, using 
the Friedewald formula [13], from total cholesterol, 
HDL-cholesterol and triglycerides. Reference systems 
have been established for these variables, as well as 
cholesterol. Although there is no primary reference 
method or material for HDL-cholesterol, a secondary 
reference method involving ultracentrifugation, Hepa-
rin-Mn2+ precipitation and quantification of cholesterol 
by the Abell-Kendall method (supervised by CDC) and 
secondary reference material of CDC frozen human 
serum pools (NIST SRM 1951b) are available [14]. 
Similarly, no primary reference procedure or material 
is available for LDL-cholesterol, however, a second-
ary reference procedure involving beta-quantification 
of cholesterol in the ultracentrifuge bottom fraction 
(density greater than 1.006 kg/L) by the Abell-Kendall 
method, and then a calculation as described [14]. 
NIST has developed a primary reference procedure 
for triglycerides using liquid chromatography-mass 
spectrometry technology, and tripalmitin (NIST SRM 
1595) is the primary reference material. A secondary 
reference procedure developed by CDC involves 
methylene chloride extraction combined with silicic 
acid treatment, ethanolic-KOH hydrolysis, oxidation 
by metaperiodate and colour development with 
chromotropic acid [14]. Lipoprotein(a), Apo-A1 and 
ApoB also have reference procedures and materials 
available [14]. 
Rolling out traceable clinical 
cholesterol assays to routine  
clinical laboratories
The establishment of traceability for clinical labor-
atory assays is a large project because of the great 
number of laboratories, wide range of assays and the 
number of specimens processed by each of the clinical 
laboratories. For example, in the USA alone there are 
over 150,000 laboratories providing blood cholesterol 
assays for patients. Consequently, an approach to 
individual laboratories, to ensure that their cholesterol 
assays were traceable to the recognized standard, was 
not feasible. However, the overwhelming adoption of 
commercial reagents, with or without automated ana-
lytical systems, by clinical laboratories lends itself to 
a strategy of focusing on the In Vitro Diagnostic manu-
facturers, which was a much more feasible target [12].
Servicing the international In Vitro Diagnostic in-
dustry is still a large task and one which is continuing 
to grow as many new manufacturers enter the market, 
particularly from the rapidly developing geographical 
areas, including Eastern Europe and Asia. This strategy 
of servicing the In Vitro Diagnostic industry requires 
considerable resources to meet time deadlines for 
production, as well as accommodate the quantity of 
analyses and secondary reference materials that is 
required. Therefore, it was considered essential to es-
tablish a network of reference laboratories distributed 
internationally. Each reference laboratory was only 
accepted into the network after demonstrating long-
term support for performing the reference assay and 
expertise to maintain performance of the Abell-Kendall 
assay to a high standard [12]. 
Reference laboratories demonstrate their accept-
able performance by participating in an external quality 
assurance program using fresh frozen human serum 
specimens calibrated by CDC. Requirements for the 
performance of blood cholesterol assays have been 
used to set the standard for reference laboratories with 
an assay CV less than 1% and a Bias of plus or minus 1%. 
These are significantly tighter limits than required for 
laboratories providing a clinical service. These CDC 
accredited reference laboratories are authorized to 
provide Certificates of Traceability to IVD manufacturers 
and laboratories [12]. 
With the establishment of the network of reference 
laboratories the CDC-National Heart, Lung and Blood 
Institute (National Institutes of Health) Lipid Standard-
ization Program was created [11]. The overall structure 
and relationships between stakeholders of the Choles-
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terol Reference Measurement Laboratory Network for 
establishing traceability of clinical cholesterol assays in 
practice is summarized in Figure 1. The calibration hier-
archy and metrological traceability for blood cholesterol 
measurement, upon which traceability of cholesterols is 
based, is presented in Figure 2. The number and types 
of institutions accessing the cholesterol reference mea-
surement procedure, including the network of reference 
laboratories, involves some 100 laboratories, 60% of 
which are located in the US and make up about 60% of 
all users. Another 27% of users are academic hospitals 
and institutes and commercial clinical trial laboratories, 
whereas government and public health laboratories 
make up a further 9% and the IVD industry about 2% 
of users [15].
Clinical impact of the lipid 
standardization program
CVD death rates and blood cholesterol levels
The current death rates (2011) from cardiovascu-
lar disease (CVD) for a number of selected countries 
around the world are presented in Table 1. They indicate 
a wide range amongst various countries, with levels in 
Russia and Eastern Europe amongst the highest rates, 
and the lowest rates observed in Sweden, Australia and 
France [17]. Death rates have varied markedly with time, 
especially in many of those countries which currently 
have the lower rates. It has been estimated that during 
the period 1965 to 1990, CVD related mortality fell by 
some 50% in Australia, Canada, France, and the United 
States, and by 60% in Japan [18]. The variation in death 
rates for the US is presented in Figure 3 demonstrating 
a peak around the 1950’s and a relatively constant 
reduction which continues to this day [19].
How have these reductions in death rates been 
achieved? It has been viewed that identification of ma-
jor risk factors through population-based studies and 
clinical trials, and effective control strategies combining 
community education and targeted management of 
high risk individuals have contributed to the fall in CVD 
mortality rates [16]. A range of medical procedures 
have been introduced to improve the care of patients 
with CVD. More specifically, for blood cholesterol levels 
data are available indicating a fall in average serum 
cholesterol levels in representative samples of the US 
population as recruited for the National Health and 
Nutrition Examination Surveys (NHANES), as well as 
the number of people with the highest levels of choles-
terol. Between 1988–1994 and 1999–2002, the average 
Figure 1. Structure of the Cholesterol Reference Measurement Laboratory Network and relationships between each of 
the stakeholders ([12] and Dr David Bunk, NIST personal communication). NIST — National Institute of Science and 
Technology; CSTL — Center for Science Teaching and Learning; CDC — Centers for Disease Control and Prevention; 
SRMs — Standard Reference Materials; A/K — Reference method: Abell-Kendall reference method for cholesterol assay; 
QC — quality control
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Figure 2. Extensive calibration hierarchy and metrological traceability to SI for cholesterol. ID-MS — isotope dilution-
mass spectroscopy definitive method for cholesterol assay
Table 1. International cardiovascular disease statistics 
(WHO, 2011) [16]
Country Deaths/100,000 persons
Ukraine 400
Russia 297
India 166
Poland 122
USA 81
China 80
Sweden 71
United Kingdom 69
Australia 60
France 29
 
serum cholesterol level of adults aged 20 years or older 
decreased from 206 mg/dL (5.34 mmol/L) to 203 mg/dL 
(5.26 mmol/L) (p = 0.009), and LDL cholesterol levels 
decreased from 129 mg/dL (3.34 mmol/L) to 123 mg/dL 
(3.19 mmol/L) (p < 0.001) [19]. Importantly greater 
decreases were observed in men 60 years or older and 
in women 50 years or older. Perhaps most importantly, 
the percentage of adults with a total cholesterol level at 
Figure 3. Age-adjusted death rates for total cardiovascular 
disease in the United States by year; death rates are per 
100,000 persons [19]
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least 240 mg/dL (greater than or equal to 6.22 mmol/L) 
decreased from 20% during 1988–1994 to 17% during 
1999–2002 (p < 0.001). These later effects are likely to 
have a greater effect of reducing deaths from CVD than 
changes to the population average serum cholesterol 
level, which is a blunt variable. These figures must be 
considered with a caveat since the data were generated 
by different assays across the various surveys although 
this was a period when traceability of blood cholesterol 
assays was being implemented.
Improved cholesterol measurement accuracy 
saves health care dollars
Another key performance indicator of healthcare 
is cost and calculations regarding savings to the 
healthcare costs in the USA alone arising from the 
improvement of performance of blood cholesterol as-
says which have been made (Dr David Bunk, personal 
communication). Based on known performances of 
cholesterol assays in 1949, there was a false positive 
and false negative rate for diagnosis of hypercholes-
terolemia of 24% in the US. Such a figure means that 
24% of patients were placed on treatment when they 
did not need it, and 24% of patients did not receive 
treatment when they needed it, which consequently 
increased their risk of a CVD event. This rate reduced 
to 19% by 1969, to 11% by 1980, 6.4% by 1986 and 
from 1990 to 1994 it was between 5.5 and 7.2%. It was 
estimated that the improvement of blood cholesterol 
measurements between 1969 and the end of the 20th 
century saved $100 M per year in the USA alone for 
unneeded treatment costs.
Conclusions
The standardization of lipid measurements, includ-
ing procedures for cholesterol, HDL-cholesterol and 
triglycerides, has been successfully achieved interna-
tionally. This has provided traceability of routine clinical 
assays to internationally recognized standard reference 
materials. The accuracy and precision of routine clinical 
assays for cholesterol, HDL-C, LDL-C and triglycerides 
have been markedly improved and clinical decision 
limits defined. These developments have been asso-
ciated with reduction in mean population cholesterol 
levels in countries where laboratories have ensured the 
use of assays traceable to internationally recognized 
standard reference materials. Most importantly, these 
developments have been associated with a decline in 
the death rate from CVD. Many improvements in the 
treatment of cardiovascular disease have been adopt-
ed over this period and, therefore, it is impossible to 
assign a specific level of reduction in the death rate for 
CVD as a result of the adoption of traceability of clinical 
cholesterol assays although it is likely that this activity 
has made an important contribution.
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